YnetnewsHealth
Teva's Experimental Celiac Drug Shows Promise in Clinical Trial
Summarized from Ynetnews by baba
CenterNeutral tone
Plus
Teva Pharmaceuticals' experimental celiac drug, TEV ‘408, significantly reduced gluten-induced intestinal damage and symptoms in a Phase 2a trial. The antibody inhibits IL-15 and has received Fast Track designation from the FDA.
The story in 6 lines · by baba
- Teva's experimental celiac drug TEV ‘408 showed significant protection against gluten damage in a trial.
- The drug reduced intestinal damage and inflammation compared to placebo.
- Patients treated with TEV ‘408 also reported fewer gastrointestinal symptoms.
- TEV ‘408 inhibits the protein interleukin-15, implicated in celiac disease.
- The drug received Fast Track designation from the U.S. FDA for celiac disease.
- Teva is also exploring TEV ‘408 for the autoimmune disease vitiligo.
Ynetnews publishes in English. The key points are summarized above. Read Ynetnews’s full report from the link at the top of the page.
